Telix Pharmaceuticals Ltd (TLX) FinancialsTLXTelix Pharmaceuticals Ltd

In the context of the broader market, TLX competes directly with industry leaders such as COGT and CRSP. With a market capitalization of $3.69B, it holds a significant position in the sector. When comparing efficiency, TLX's gross margin of N/A stands against COGT's N/A and CRSP's 100.00%. Such benchmarking helps identify whether Telix Pharmaceuticals Limited is trading at a premium or discount relative to its financial performance.

The stock has a high forward P/E of 140.85 and a current price of $10.69, with a recent 5-day change of -4.64%.